Mercator Medical S.A., together with its subsidiaries, produces medical gloves and distributes medical disposables in Europe and Russia. More Details
Flawless balance sheet and good value.
Share Price & News
How has Mercator Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MRC is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: MRC's weekly volatility has decreased from 21% to 14% over the past year, but is still higher than 75% of Polish stocks.
7 Day Return
PL Medical Equipment
1 Year Return
PL Medical Equipment
Return vs Industry: MRC exceeded the Polish Medical Equipment industry which returned 845.1% over the past year.
Return vs Market: MRC exceeded the Polish Market which returned -5.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Mercator Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StHow Does Mercator Medical's (WSE:MRC) CEO Pay Compare With Company Performance?
2 months ago | Simply Wall StMercator Medical S.A.'s (WSE:MRC) Stock Is Going Strong: Is the Market Following Fundamentals?
3 months ago | Simply Wall StWe Think Mercator Medical (WSE:MRC) Can Stay On Top Of Its Debt
Is Mercator Medical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MRC (PLN510) is trading below our estimate of fair value (PLN6952.13)
Significantly Below Fair Value: MRC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MRC is good value based on its PE Ratio (9.2x) compared to the XE Medical Equipment industry average (42.8x).
PE vs Market: MRC is good value based on its PE Ratio (9.2x) compared to the Polish market (12.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MRC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MRC is overvalued based on its PB Ratio (7.9x) compared to the PL Medical Equipment industry average (3.8x).
How is Mercator Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if MRC's forecast earnings growth is above the savings rate (2.9%).
Earnings vs Market: Insufficient data to determine if MRC's earnings are forecast to grow faster than the Polish market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MRC's revenue is expected to decline over the next 3 years (-0.9% per year).
High Growth Revenue: MRC's revenue is forecast to decline over the next 3 years (-0.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MRC's Return on Equity is forecast to be high in 3 years time
How has Mercator Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRC has high quality earnings.
Growing Profit Margin: MRC became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: MRC's earnings have grown significantly by 84% per year over the past 5 years.
Accelerating Growth: MRC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MRC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-4.6%).
Return on Equity
High ROE: MRC's Return on Equity (85.4%) is considered outstanding.
How is Mercator Medical's financial position?
Financial Position Analysis
Short Term Liabilities: MRC's short term assets (PLN705.8M) exceed its short term liabilities (PLN202.6M).
Long Term Liabilities: MRC's short term assets (PLN705.8M) exceed its long term liabilities (PLN4.9M).
Debt to Equity History and Analysis
Debt Level: MRC's debt to equity ratio (0.09%) is considered satisfactory.
Reducing Debt: MRC's debt to equity ratio has reduced from 73.1% to 0.09% over the past 5 years.
Debt Coverage: MRC's debt is well covered by operating cash flow (89518.8%).
Interest Coverage: MRC's interest payments on its debt are well covered by EBIT (122x coverage).
What is Mercator Medical current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MRC's dividend (0.098%) isn’t notable compared to the bottom 25% of dividend payers in the Polish market (1.83%).
High Dividend: MRC's dividend (0.098%) is low compared to the top 25% of dividend payers in the Polish market (5.61%).
Stability and Growth of Payments
Stable Dividend: MRC is not paying a notable dividend for the Polish market, therefore no need to check if payments are stable.
Growing Dividend: MRC is not paying a notable dividend for the Polish market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: MRC is not paying a notable dividend for the Polish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MRC's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Wieslaw Zyznowski (56 yo)
Dr. Wieslaw Zyznowski has been the Chairman of Management Board at Mercator Medical Spólka Akcyjna since 2010. In the 90s Dr. Zyznowski co-founded the Mercator. From 1991 to 2001 he served as (apart from a...
CEO Compensation Analysis
Compensation vs Market: Wieslaw's total compensation ($USD125.36K) is below average for companies of similar size in the Polish market ($USD834.33K).
Compensation vs Earnings: Wieslaw's compensation has been consistent with company performance over the past year.
|Chairman of Management Board||10.83yrs||zł470.10k||3.94% |
|Vice-President of the Management Board & Financial Director||1.83yrs||zł558.70k||0.089% |
|Member of the Management Board||1yr||zł6.30k||0.032% |
Experienced Management: MRC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|Member of Supervisory Board||6.42yrs||zł26.40k||no data|
|Chairwoman of Supervisory Board||10.83yrs||zł50.40k||0.16% |
|Vice Chairman of Supervisory Board||no data||zł26.40k||0.029% |
|Independent Member of Supervisory Board||7.25yrs||zł26.40k||no data|
|Member of the Supervisory Board||no data||zł50.20k||no data|
Experienced Board: MRC's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Mercator Medical S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Mercator Medical S.A.
- Ticker: MRC
- Exchange: WSE
- Founded: 1989
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: zł5.199b
- Shares outstanding: 10.59m
- Website: https://mercatormedical.eu
Number of Employees
- Mercator Medical S.A.
- Ul. H. Modrzejewskiej 30
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MRC||WSE (Warsaw Stock Exchange)||Yes||Bearer Shares||PL||PLN||Jan 2014|
|0QJM||LSE (London Stock Exchange)||Yes||Bearer Shares||GB||PLN||Jan 2014|
|MM2||BST (Boerse-Stuttgart)||Yes||Bearer Shares||DE||EUR||Jan 2014|
Mercator Medical S.A., together with its subsidiaries, produces medical gloves and distributes medical disposables in Europe and Russia. The company offers surgical gloves for conducting invasive surgeries...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/30 18:08|
|End of Day Share Price||2020/11/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.